Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 16 | 2021 | 275 | 5.470 |
Why?
|
| Kidney Failure, Chronic | 17 | 2021 | 534 | 4.720 |
Why?
|
| Catheterization, Central Venous | 4 | 2017 | 62 | 1.700 |
Why?
|
| African Americans | 13 | 2019 | 1335 | 1.690 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2017 | 46 | 1.440 |
Why?
|
| Kidney Diseases | 9 | 2021 | 243 | 1.370 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2018 | 1437 | 1.340 |
Why?
|
| Apolipoproteins | 10 | 2019 | 194 | 1.170 |
Why?
|
| Albuminuria | 5 | 2015 | 172 | 1.110 |
Why?
|
| Lipoproteins, HDL | 9 | 2016 | 250 | 1.020 |
Why?
|
| Uric Acid | 2 | 2018 | 26 | 0.920 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2018 | 293 | 0.850 |
Why?
|
| Catheters, Indwelling | 2 | 2014 | 42 | 0.750 |
Why?
|
| Humans | 40 | 2021 | 32273 | 0.700 |
Why?
|
| Middle Aged | 24 | 2019 | 11840 | 0.610 |
Why?
|
| Fluid Therapy | 1 | 2019 | 25 | 0.600 |
Why?
|
| Male | 27 | 2019 | 19438 | 0.590 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2015 | 821 | 0.580 |
Why?
|
| Catheter-Related Infections | 2 | 2019 | 9 | 0.570 |
Why?
|
| Psoas Muscles | 1 | 2018 | 16 | 0.540 |
Why?
|
| Female | 25 | 2019 | 19945 | 0.540 |
Why?
|
| Patient Selection | 1 | 2019 | 272 | 0.530 |
Why?
|
| Hyperuricemia | 2 | 2018 | 11 | 0.520 |
Why?
|
| Heparin | 1 | 2017 | 65 | 0.500 |
Why?
|
| Aged | 15 | 2019 | 10250 | 0.480 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2016 | 61 | 0.470 |
Why?
|
| Anticoagulants | 1 | 2017 | 122 | 0.470 |
Why?
|
| Molecular Motor Proteins | 3 | 2012 | 59 | 0.470 |
Why?
|
| Kidney | 4 | 2021 | 521 | 0.470 |
Why?
|
| Myosin Heavy Chains | 3 | 2012 | 84 | 0.470 |
Why?
|
| Kidney Glomerulus | 2 | 2014 | 28 | 0.460 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2013 | 1050 | 0.430 |
Why?
|
| Hypertension | 2 | 2012 | 980 | 0.410 |
Why?
|
| Diabetes Complications | 1 | 2015 | 171 | 0.400 |
Why?
|
| Receptors, Notch | 2 | 2010 | 16 | 0.390 |
Why?
|
| Risk Factors | 11 | 2017 | 3933 | 0.390 |
Why?
|
| Gout | 1 | 2012 | 13 | 0.380 |
Why?
|
| Diabetic Nephropathies | 2 | 2013 | 223 | 0.380 |
Why?
|
| Chemokine CCL2 | 1 | 2012 | 48 | 0.370 |
Why?
|
| Serum Albumin | 1 | 2012 | 56 | 0.370 |
Why?
|
| Cognition Disorders | 1 | 2015 | 349 | 0.360 |
Why?
|
| Anti-Bacterial Agents | 2 | 2011 | 324 | 0.350 |
Why?
|
| Proteinuria | 1 | 2012 | 52 | 0.350 |
Why?
|
| Environmental Exposure | 1 | 2012 | 60 | 0.350 |
Why?
|
| Minocycline | 1 | 2011 | 11 | 0.350 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 150 | 0.340 |
Why?
|
| Length of Stay | 1 | 2012 | 321 | 0.340 |
Why?
|
| Bacteremia | 1 | 2011 | 66 | 0.330 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 3893 | 0.320 |
Why?
|
| Fatty Acids | 1 | 2010 | 100 | 0.310 |
Why?
|
| Prognosis | 5 | 2018 | 1529 | 0.300 |
Why?
|
| Hospitalization | 1 | 2012 | 475 | 0.300 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 179 | 0.300 |
Why?
|
| DNA | 1 | 2010 | 223 | 0.290 |
Why?
|
| Risk Assessment | 4 | 2019 | 1423 | 0.280 |
Why?
|
| Brain | 1 | 2015 | 966 | 0.270 |
Why?
|
| Glomerular Filtration Rate | 6 | 2015 | 302 | 0.270 |
Why?
|
| Acetyl-CoA Carboxylase | 3 | 2013 | 22 | 0.260 |
Why?
|
| Adult | 14 | 2019 | 9261 | 0.250 |
Why?
|
| Treatment Outcome | 3 | 2021 | 3408 | 0.250 |
Why?
|
| Signal Transduction | 1 | 2010 | 727 | 0.240 |
Why?
|
| Tumor Virus Infections | 2 | 2018 | 21 | 0.240 |
Why?
|
| Polyomavirus Infections | 2 | 2018 | 20 | 0.240 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 1159 | 0.230 |
Why?
|
| Kidney Transplantation | 1 | 2010 | 490 | 0.230 |
Why?
|
| North Carolina | 3 | 2021 | 1300 | 0.230 |
Why?
|
| Genetic Variation | 3 | 2015 | 248 | 0.210 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2013 | 81 | 0.190 |
Why?
|
| Prevalence | 3 | 2016 | 955 | 0.190 |
Why?
|
| Adolescent | 4 | 2021 | 3516 | 0.180 |
Why?
|
| Age Factors | 2 | 2016 | 1178 | 0.180 |
Why?
|
| Incidence | 2 | 2016 | 1242 | 0.180 |
Why?
|
| Time Factors | 3 | 2017 | 2203 | 0.180 |
Why?
|
| Ultrafiltration | 2 | 2019 | 10 | 0.170 |
Why?
|
| Membrane Proteins | 2 | 2013 | 243 | 0.170 |
Why?
|
| Prospective Studies | 3 | 2017 | 2316 | 0.170 |
Why?
|
| Quality of Life | 2 | 2016 | 969 | 0.160 |
Why?
|
| Retrospective Studies | 3 | 2018 | 3609 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2012 | 1840 | 0.150 |
Why?
|
| United States | 3 | 2015 | 4069 | 0.150 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 264 | 0.150 |
Why?
|
| Genome-Wide Association Study | 2 | 2012 | 543 | 0.150 |
Why?
|
| Survival Rate | 2 | 2018 | 892 | 0.150 |
Why?
|
| Weight Gain | 1 | 2019 | 104 | 0.140 |
Why?
|
| Knowledge | 1 | 2018 | 13 | 0.140 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2238 | 0.140 |
Why?
|
| Forecasting | 1 | 2019 | 144 | 0.140 |
Why?
|
| Peritoneal Dialysis | 1 | 2018 | 22 | 0.140 |
Why?
|
| Outpatients | 1 | 2018 | 57 | 0.140 |
Why?
|
| Cisplatin | 1 | 2018 | 77 | 0.130 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 759 | 0.130 |
Why?
|
| Health Status Indicators | 1 | 2018 | 69 | 0.130 |
Why?
|
| Stroke Volume | 1 | 2021 | 417 | 0.130 |
Why?
|
| JC Virus | 2 | 2018 | 20 | 0.130 |
Why?
|
| African Continental Ancestry Group | 3 | 2016 | 338 | 0.130 |
Why?
|
| Kidney Function Tests | 2 | 2015 | 101 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2018 | 476 | 0.130 |
Why?
|
| Mitochondrial Diseases | 1 | 2016 | 11 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 156 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 137 | 0.120 |
Why?
|
| Body Composition | 1 | 2018 | 327 | 0.120 |
Why?
|
| Linear Models | 2 | 2014 | 426 | 0.120 |
Why?
|
| RNA, Messenger | 2 | 2014 | 499 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 650 | 0.110 |
Why?
|
| Young Adult | 4 | 2018 | 2651 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 65 | 0.110 |
Why?
|
| Comorbidity | 1 | 2016 | 563 | 0.110 |
Why?
|
| Hepatocytes | 1 | 2015 | 80 | 0.110 |
Why?
|
| Mesangial Cells | 1 | 2014 | 9 | 0.110 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2014 | 39 | 0.100 |
Why?
|
| Genotype | 4 | 2019 | 702 | 0.100 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 327 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1480 | 0.100 |
Why?
|
| Autoantigens | 1 | 2013 | 15 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 164 | 0.100 |
Why?
|
| Glomerulonephritis | 1 | 2013 | 19 | 0.100 |
Why?
|
| European Continental Ancestry Group | 2 | 2015 | 1076 | 0.100 |
Why?
|
| Podocytes | 2 | 2014 | 19 | 0.100 |
Why?
|
| Disease Progression | 2 | 2019 | 591 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 904 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 146 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 83 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 772 | 0.090 |
Why?
|
| Family Health | 1 | 2012 | 73 | 0.090 |
Why?
|
| Metabolism | 1 | 2011 | 7 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2012 | 164 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 133 | 0.080 |
Why?
|
| Genome, Human | 1 | 2011 | 130 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2011 | 236 | 0.080 |
Why?
|
| Thienamycins | 1 | 2010 | 4 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 880 | 0.080 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2010 | 36 | 0.080 |
Why?
|
| Lupus Nephritis | 1 | 2010 | 29 | 0.080 |
Why?
|
| Oxidation-Reduction | 1 | 2010 | 274 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2013 | 863 | 0.080 |
Why?
|
| Genetic Association Studies | 3 | 2015 | 146 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 1212 | 0.070 |
Why?
|
| Critical Illness | 1 | 2010 | 87 | 0.070 |
Why?
|
| Intensive Care Units | 1 | 2010 | 121 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 544 | 0.070 |
Why?
|
| Gene Frequency | 3 | 2013 | 211 | 0.070 |
Why?
|
| Obesity | 1 | 2013 | 1111 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2018 | 854 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2016 | 839 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 287 | 0.050 |
Why?
|
| Phenotype | 2 | 2013 | 622 | 0.040 |
Why?
|
| Adipose Tissue | 2 | 2013 | 320 | 0.040 |
Why?
|
| Mice | 2 | 2015 | 2571 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 312 | 0.030 |
Why?
|
| Animals | 3 | 2015 | 8196 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2015 | 23 | 0.030 |
Why?
|
| Autophagy | 1 | 2015 | 55 | 0.030 |
Why?
|
| Proteomics | 1 | 2015 | 97 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 290 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 359 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 93 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 478 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 257 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2013 | 13 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 43 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2014 | 132 | 0.020 |
Why?
|
| Biopsy | 1 | 2014 | 249 | 0.020 |
Why?
|
| Cell Line | 1 | 2014 | 454 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 595 | 0.020 |
Why?
|
| Cystatin C | 1 | 2013 | 33 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 77 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 727 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2014 | 123 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2013 | 55 | 0.020 |
Why?
|
| Demography | 1 | 2013 | 101 | 0.020 |
Why?
|
| Indians, North American | 1 | 2013 | 75 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 305 | 0.020 |
Why?
|
| Heredity | 1 | 2012 | 12 | 0.020 |
Why?
|
| Pedigree | 1 | 2012 | 136 | 0.020 |
Why?
|
| Triglycerides | 1 | 2013 | 235 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 454 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 186 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 1895 | 0.020 |
Why?
|
| Gene Expression | 1 | 2011 | 346 | 0.020 |
Why?
|
| Liver | 1 | 2013 | 492 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2010 | 85 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 213 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 854 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2011 | 458 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 716 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 520 | 0.020 |
Why?
|